Compare Cytokinetics Inc (CYTK) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Vital Farms Inc — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while Vital Farms Inc trades at $9.45 (market cap $405.27M). The key difference: Cytokinetics Inc is far larger — about 21.3× Vital Farms Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Vital Farms Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Vital Farms Inc for 14 Days on average.
| CYTK | VITL | |
|---|---|---|
Market Cap | $8.62B | $405.27M |
Volume | 2,594,626 | 1,810,837 |
Sector | Health | Consumer Staples |
52-Week High | $87.26 | $43.68 |
52-Week Low | $54.76 | $8.28 |
Typical Hold Time | 19 Days | 14 Days |
Enterprise Value | $8.72B | $492.28M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
Vital Farms (VITL) trades at $9.24, down 1.7% on the day, reflecting ongoing pressure from weak earnings and industry headwinds. The stock shows a bearish technical trend with key support at $9.00, while fundamentals reveal a sharp decline in profitability with a net margin of just 0.02% in 2026. Recent news highlights strategic review discussions and institutional acquisitions, yet negative cash flow and pricing challenges in the egg market weigh on investor confidence.
The outlook remains cautious with significant execution risks amid industry oversupply, though analyst consensus suggests upside potential to a $13.11 price target. Investment opportunity hinges on a successful strategic review and margin recovery, but risks include sustained cash burn and competitive pressures that could limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
